Navigation Links
Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment

A retrospective analysis of methotrexate (MTX) safety data found that injection of this disease-modifying anti-rheumatic drug (DMARD) was not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis (JIA). Findings published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), suggest that with similar efficacy and tolerability the more comfortable oral approach may be more suitable to treat pediatric arthritis patients.

There are a number of chronic arthritis conditions, collectively referred to as JIA, that affect children and teens. Medical evidence reports JIA incidence ranges from 10 to 100 per 100,000 children under 16 years of age, making it the most common chronic pediatric inflammatory disease. In the U.S. the ACR estimates that 294,000 children are diagnosed with JIA, which can lead to severe disability.

Previous studies have confirmed the safety and efficacy of MTX, which is one of most common first line DMARD treatments for arthritis. While side effects such as nausea and vomiting may limit MTX use in children, the type of delivery method may also pose a significant burden to the patients," explains Dr. Ariane Klein from Asklepios Klinik in Sankt Augustin, Germany. "Our study compares the efficacy of oral MTX to injection of the drug and to assess side effects in children with JIA."

Using data collected by the German Methotrexate Registry since 2005, researchers identified JIA patients who were treated with MTX for at least 6 months and who did not receive additional biologic therapies. Participants who changed their MTX approach during the observation period were excluded. The study groups consisted of 259 (63%) patients who received oral MTX and 152 (32%) patients receiving MTX injections. In both groups, patients had a median age of ten years, two-thirds were female, and all received a comparable dose of MTX.

A clinical response (efficacy) based on the PedACR 30 score after six months of MTX therapy was found in 72% receiving oral therapy and 73% of patients using injections. At least one adverse event was reported in 22% of patients in the oral cohort compared to 27% in the injection therapy group. Researchers found that significantly more patients receiving MTX injections discontinued treatment due to adverse events compared to those on oral treatment at 11% versus 5%, respectively.

Dr. Klein concludes, "Our analysis found that efficacy and tolerability of MTX was similar in both delivery methods. The often unpopular MTX injection did not appear to be superior to oral administration and may likely be spared without clinical consequences." The authors advised further controlled studies to determine the best application route of MTX treatment in patients with juvenile arthritis."

Contact: Dawn Peters

Related medicine news :

1. FDA Issues Warning on Fat-Melting Spa Injections
2. Injection Helps Treat Hard-to-Control Type 2 Diabetes
3. Botox Injections May Relieve Tennis Elbow Pain
4. Botulinum injection provides relief of tennis elbow
5. X-ray guided steroid injections effectively treat hamstring tendonitis, study suggests
6. Nanosponge drug delivery system more effective than direct injection
7. Tiger Takes Another Shot: PRP Injections Put On the Spot
8. Insulin Pump With Blood Sugar Sensor May Improve on Injections
9. Transforaminal steroid injection for lumbar radicular pain proves superior to placebo
10. Will Loss of Lethal Injection Drug Harm Surgical Patients?
11. Study finds little decline in hepatitis C infections among injection drug users
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... With FCPX Overlay: Grit , users can apply a ... possibilities are truly endless, all with a click of a mouse. Each user has ... flip, depth of field and more, all within Final Cut Pro X. , With ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes ... and support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact ...
(Date:11/30/2015)... Turks & Caicos Islands, BWI (PRWEB) , ... December 01, 2015 ... ... in 2015. Recently Caribbean Journal, one of the leading digital news sites highlighting ... The top reason? The weather. While much of North America shivers under chilly ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... the19th Bi-National Convention of the Federation of Philippine American Chambers of Commerce held ... Vegas, Nevada. , 1Heart Caregiver Services, as an active delegate from the ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 ... "Orphan Drugs Market 2015-2019" report to their ... the addition of the "Orphan Drugs Market ... Research and Markets ( ) has ... Market 2015-2019" report to their offering. ...
(Date:11/30/2015)... Nov. 30, 2015   Royal Philips (NYSE: ... the industry,s first MRI guided user interface and automatic ... patients with MR Conditional implants, such as knee and ... 2015 Radiological Society of North America Annual Meeting (RSNA) ... supports diagnostic confidence of this growing patient population. ScanWise ...
(Date:11/30/2015)... November 30, 2015 ... adds a 2015 publication ... - 2015 with comprehensive analysis of ... of deal types, such as Mergers ... . ...
Breaking Medicine Technology: